Avoiding pitfalls in antibiotic therapy: the antibiotic stewardship approach
DOI:
https://doi.org/10.54502/msuceva.v2n2a1Palabras clave:
ABS interventions, antibiotic policies, clinical practice, dosing regimen, ICU, Multi Drug Resistance (MDR), severe side effectsResumen
The aim of this reflection is to determine the effectiveness and safety of ABS interventions. A strong correlation between antibiotic overuse and the growing worldwide resistance, but also with individual side effects is well established and should open the door to a more personalized approach to anti-infective therapies. Antibiotic resistance is a global public health challenge and is recognized as a global threat to human health by national healthcare agencies, governments, medical societies and the World Health Organization (WHO). The anticipated clinical scenario of Pan- Drug – Resistant (PDR) bacteria is accelerated by antibiotic overuse. In fact, multi- drug – resistance (MDR) is already the cause of severe infections, complications, longer hospital stay and increased mortality in most of the countries. Herein, the techniques of an Antibiotic Stewardship Approach and their stepwise implementation are summarized and highlighted. There is often a general lack of understanding on how to choose the right antibiotic at the right time and in the right dose. This article discusses general principles like the best choice and use of different antibiotic classes, a better use of beta- lactams according to principles of pharmacokinetics, avoidance or limitation of unnecessary combination therapies, shorter courses of therapy without any disadvantage in infection control and the value of PCT monitoring. We hope to contribute to the promotion and implementation of these important therapeutical principles, aiming at the reduction of unnecessary or wrong antibiotic therapies and, so, at the decrease of side effects, mortality and further resistance.
Descargas
Métricas
Citas
ECDC- European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe 2017. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: 2018. https://www.ecdc.europa.eu/sites/default/files/documents/AMR%202017_Cover%2BInner-web_v3.pdf.
Falagas ME, Karageorgopoulos DE. Pandrug Resistance (PDR), Extensive Drug Resistance (XDR), and Multidrug Resistance (MDR) among Gram‐Negative Bacilli: Need for International Harmonization in Terminology. Clinical Infectious Diseases 2008;46:1121–2.
https://doi.org/10.1086/528867 DOI: https://doi.org/10.1086/528867
The New York Times. Penicillin´s finder assays its future; Sir Alexander Fleming Says Improved Dosage Method Is Needed to Extend Use Other Scientists Praised Self-Medication Decried 1945:21.
Khanna S, Pardi DS. Clostridium difficile infection: management strategies for a difficult disease. Therap Adv Gastroenterol 2014;7:72–86.
https://doi.org/10.1177/1756283X13508519 DOI: https://doi.org/10.1177/1756283X13508519
Davey P, Brown E, Fenelon L, Finch R, Gould I, Hartman G, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. In: Davey P, editor. Cochrane Database of Systematic Reviews, Chichester, UK: John Wiley & Sons, Ltd; 2005.
https://doi.org/10.1002/14651858.CD003543.pub2 DOI: https://doi.org/10.1002/14651858.CD003543.pub2
Aslam B, Wang W, Arshad MI, Khurshid M, Muzammil S, Rasool MH, et al. Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist 2018;Volume 11:1645–58. https://doi.org/10.2147/IDR.S173867 DOI: https://doi.org/10.2147/IDR.S173867
Dellit TH, Owens RC, McGowan JE, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship. Clinical Infectious Diseases 2007;44:159–77. https://doi.org/10.1086/510393 DOI: https://doi.org/10.1086/510393
Kollef MH, Micek ST. Antimicrobial stewardship programs: mandatory for all ICUs. Crit Care 2012;16:179. https://doi.org/10.1186/cc11853 DOI: https://doi.org/10.1186/cc11853
Bartlett JG, Gilbert DN, Spellberg B. Seven Ways to Preserve the Miracle of Antibiotics. Clinical Infectious Diseases 2013;56:1445–50.
https://doi.org/10.1093/cid/cit070 DOI: https://doi.org/10.1093/cid/cit070
AWMF. S3- Leitlinie Strategien zur Sicherung rationaler Antibiotika-Anwendung im Krankenhaus. 2018. https://www.antibiotic-stewardship.de/fileadmin/media/initiative/Langfassung_der_Leitlinie_Strategien_zur_Sicherung_rationaler_Antibiotika-Anwendung_im_Krankenhaus.pdf
Bodmann K, Grabein B, Kresken M. Kalkulierte parenterale initialtherapie bakterieller erkrankungen bei erwachsenen – update 2018. 2018. https://www.p-e-g.org/files/content/Service/Empfehlungen-Leitlinien/PEG-S2k-Leitlinie-Update-2018.pdf DOI: https://doi.org/10.1055/s-0043-114874
Schouten J. Antimicrobial Stewardship in the ICU. ICU Management & Practice 2018;17:21–4.
https://healthmanagement.org/uploads/article_attachment/icu-v17-schouten-antimicrobial.pdf.
Luyt C-E, Bréchot N, Trouillet J-L, Chastre J. Antibiotic stewardship in the intensive care unit. Crit Care 2014;18:480. https://doi.org/10.1186/s13054-014-0480-6 DOI: https://doi.org/10.1186/s13054-014-0480-6
Mutters NT, de Angelis G, Restuccia G, di Muzio F, Schouten J, Hulscher M, et al. Use of evidence-based recommendations in an antibiotic care bundle for the intensive care unit. Int J Antimicrob Agents 2018;51:65–70. https://doi.org/10.1016/j.ijantimicag.2017.06.020 DOI: https://doi.org/10.1016/j.ijantimicag.2017.06.020
Baur D, Gladstone BP, Burkert F, Carrara E, Foschi F, Döbele S, et al. Effect of antibiotic stewardship on the incidence of infection and colonization with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis 2017;17:990–1001. https://doi.org/10.1016/S1473-3099(17)30325-0 DOI: https://doi.org/10.1016/S1473-3099(17)30325-0
Davey P, Marwick CA, Scott CL, Charani E, McNeil K, Brown E, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database of Systematic Reviews 2017;2017. https://doi.org/10.1002/14651858.CD003543.pub4 DOI: https://doi.org/10.1002/14651858.CD003543.pub4
Berríos-Torres SI, Umscheid CA, Bratzler DW, Leas B, Stone EC, Kelz RR, et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. JAMA Surg 2017;152:784. https://doi.org/10.1001/jamasurg.2017.0904 DOI: https://doi.org/10.1001/jamasurg.2017.0904
Veiga RP, Paiva J-A. Pharmacokinetics–pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients. Crit Care 2018;22:233. https://doi.org/10.1186/s13054-018-2155-1 DOI: https://doi.org/10.1186/s13054-018-2155-1
Vardakas KZ, Voulgaris GL, Maliaros A, Samonis G, Falagas ME. Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. Lancet Infect Dis 2018;18:108–20. https://doi.org/10.1016/S1473-3099(17)30615-1 DOI: https://doi.org/10.1016/S1473-3099(17)30615-1
Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 2014;14:498–509.
https://doi.org/10.1016/S1473-3099(14)70036-2 DOI: https://doi.org/10.1016/S1473-3099(14)70036-2
Roberts JA, Joynt GM, Choi GYS, Gomersall CD, Lipman J. How to optimise antimicrobial prescriptions in the Intensive Care Unit: principles of individualised dosing using pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 2012;39:187–92.
https://doi.org/10.1016/j.ijantimicag.2011.11.002 DOI: https://doi.org/10.1016/j.ijantimicag.2011.11.002
Roberts JA, Paul SK, Akova M, Bassetti M, de Waele JJ, Dimopoulos G, et al. DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients? Clinical Infectious Diseases 2014;58:1072–83. https://doi.org/10.1093/cid/ciu027 DOI: https://doi.org/10.1093/cid/ciu027
Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ 2018:k678. https://doi.org/10.1136/bmj.k678 DOI: https://doi.org/10.1136/bmj.k678
Food and Drug Administration Safety Announcement-FDA. FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. 2018. https://www.fda.gov/drugs/drug-safety-and-availability/fda-reinforces-safety-information-about-serious-low-blood-sugar-levels-and-mental-health-side#:~:text=Safety%20Announcement,certain%20mental%20health%20side%20effects
Tandan M, Cormican M, Vellinga A. Adverse events of fluoroquinolones vs. other antimicrobials prescribed in primary care: A systematic review and meta-analysis of randomized controlled trials. Int J Antimicrob Agents 2018;52:529–40.
https://doi.org/10.1016/j.ijantimicag.2018.04.014 DOI: https://doi.org/10.1016/j.ijantimicag.2018.04.014
Food and Drug Administration Safety Announcement-FDA. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. 2016.
Tan BK, Vivier E, Bouziad KA, Zahar J-R, Pommier C, Parmeland L, et al. A hospital-wide intervention replacing ceftriaxone with cefotaxime to reduce rate of healthcare-associated infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in the intensive care unit. Intensive Care Med 2018;44:672–3. https://doi.org/10.1007/s00134-018-5079-y DOI: https://doi.org/10.1007/s00134-018-5079-y
Meletiadis J, Turlej-Rogacka A, Lerner A, Adler A, Tacconelli E, Mouton JW. Amplification of Antimicrobial Resistance in Gut Flora of Patients Treated with Ceftriaxone. Antimicrob Agents Chemother 2017;61. https://doi.org/10.1128/AAC.00473-17 DOI: https://doi.org/10.1128/AAC.00473-17
Spellberg B. The New Antibiotic Mantra—“Shorter Is Better.” JAMA Intern Med 2016;176:1254. https://doi.org/10.1001/jamainternmed.2016.3646 DOI: https://doi.org/10.1001/jamainternmed.2016.3646
Sawyer RG, Claridge JA, Nathens AB, Rotstein OD, Duane TM, Evans HL, et al. Trial of Short-Course Antimicrobial Therapy for Intraabdominal Infection. New England Journal of Medicine 2015;372:1996–2005.
https://doi.org/10.1056/NEJMoa1411162 DOI: https://doi.org/10.1056/NEJMoa1411162
Montravers P, Tubach F, Lescot T, Veber B, Esposito-Farèse M, Seguin P, et al. Short-course antibiotic therapy for critically ill patients treated for postoperative intra-abdominal infection: the DURAPOP randomised clinical trial. Intensive Care Med 2018;44:300–10. https://doi.org/10.1007/s00134-018-5088-x DOI: https://doi.org/10.1007/s00134-018-5088-x
Chotiprasitsakul D, Han JH, Cosgrove SE, Harris AD, Lautenbach E, Conley AT, et al. Comparing the Outcomes of Adults with Enterobacteriaceae Bacteremia Receiving Short-Course Versus Prolonged-Course Antibiotic Therapy in a Multicenter, Propensity Score–Matched Cohort. Clinical Infectious Diseases 2018;66:172–7. https://doi.org/10.1093/cid/cix767 DOI: https://doi.org/10.1093/cid/cix767
Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial. Clinical Infectious Diseases 2019;69:1091–8. https://doi.org/10.1093/cid/ciy1054 DOI: https://doi.org/10.1093/cid/ciy1054
Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med 2017;43:304–77. https://doi.org/10.1007/s00134-017-4683-6 DOI: https://doi.org/10.1007/s00134-017-4683-6
Garnacho-Montero J, Gutiérrez-Pizarraya A, Escoresca-Ortega A, Corcia-Palomo Y, Fernández-Delgado E, Herrera-Melero I, et al. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 2014;40:32–40. https://doi.org/10.1007/s00134-013-3077-7 DOI: https://doi.org/10.1007/s00134-013-3077-7
Tabah A, Cotta MO, Garnacho-Montero J, Schouten J, Roberts JA, Lipman J, et al. A Systematic Review of the Definitions, Determinants, and Clinical Outcomes of Antimicrobial De-escalation in the Intensive Care Unit. Clinical Infectious Diseases 2016;62:1009–17.
https://doi.org/10.1093/cid/civ1199 DOI: https://doi.org/10.1093/cid/civ1199
Thwaites GE, Scarborough M, Szubert A, Nsutebu E, Tilley R, Greig J, et al. Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomized, double-blind, placebo-controlled trial. The Lancet 2018;391:668–78.
https://doi.org/10.1016/S0140-6736(17)32456-X DOI: https://doi.org/10.1016/S0140-6736(17)32456-X
Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh P-R, Viale P, Paño-Pardo JR, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis 2017;17:726–34. https://doi.org/10.1016/S1473-3099(17)30228-1 DOI: https://doi.org/10.1016/S1473-3099(17)30522-4
de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomized, controlled, open-label trial. Lancet Infect Dis 2016;16:819–27. https://doi.org/10.1016/S1473-3099(16)00053-0 DOI: https://doi.org/10.1016/S1473-3099(16)00053-0
Schuetz P, Wirz Y, Sager R, Christ-Crain M, Stolz D, Tamm M, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis 2018;18:95–107. https://doi.org/10.1016/S1473-3099(17)30592-3 DOI: https://doi.org/10.1016/S1473-3099(18)30016-1
SCCM-Society of Critical Care Medicine. Surviving Sepsis Campaign Guidelines 2021.
https://www.sccm.org/Clinical-Resources/Guidelines/Guidelines/Surviving-Sepsis-Guidelines-2021
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2022 Huppertz Thyssen M.H. Rodríguez Saavedra C.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Magna Scientia UCEVA proporciona un acceso abierto, libre y gratuito a su contenido, basado en el principio de que ofrecer al público un acceso libre a las investigaciones, ayuda a un mayor intercambio global del conocimiento. Lo cual, implica que los usuarios pueden leer, descargar, almacenar, imprimir, buscar, indexar y realizar enlaces a los textos completos de esta revista. Se permite distribuir los diversos artículos en las versiones post-print y oficial, sin previo permiso del autor o editor, considerando que el fin de este, no implica fines comerciales, ni la generación de obras derivadas; Solo se solicita la mención de la fuente así como la autoría. El titular del copyright será el o los autores que publiquen en Magna Scientia UCEVA.
Magna Scientia UCEVA está distribuida bajo los términos de la licencia https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es